About

Dr. Katey Owen has served on Adaptive Biotechnologies' board of directors since March 2021. She joined the Bill & Melinda Gates Foundation in 2013 as Deputy Director of Vaccine Development, became Director, Neglected Tropical Diseases in 2017 and Director, Vaccine Development in November 2022, with responsibility for large vaccine and neglected-tropical-disease portfolios and the Foundation's pharmaceutical-industry engagement. Before the Gates Foundation she held roles of increasing responsibility at Merck & Co., including in Merck Vaccines, Merck Manufacturing Division and Merck Research Laboratories. She serves on the board of the Coalition for Epidemic Preparedness Innovations and as a board observer for other health organizations. Dr. Owen holds a PhD in Molecular Virology and a BS in Genetic Biology from Purdue University.

Roles

Adaptive Biotechnologies Corp.
Director · Current role
March 2021–present
Bill & Melinda Gates Foundation
Director, Vaccine Development
November 2022 - present
Bill & Melinda Gates Foundation
Director, Neglected Tropical Diseases
2017 - present
Bill & Melinda Gates Foundation
Deputy Director, Vaccine Development
2013 - 2017
Merck & Co., Inc.
Executive Director (Merck Vaccines); Sr. Director (Merck Manufacturing); Director (Merck Research Laboratories)
before 2013

External Roles

Coalition for Epidemic Preparedness Innovations
Director
The End Fund
Board observer
VitriVax, Inc.
Board observer

Director Compensation

FY 2025
Fees earned or paid in cash
$60,000
Component$60,000 annual cash retainer plus any lead-director/committee-chair fees earned in FY2025
Option awards
$124,998
ComponentAnnual stock option grant, ASC 718 grant-date fair value
Stock awards
$124,999
ComponentAnnual RSU grant, ASC 718 grant-date fair value
Total
$309,997

Also at Adaptive Biotechnologies Corp.

Related

See how VectorShift works for your firm

Request Demo